Citations

Showing 10 of 108104 citations.

Open-Source Whole Slide Image Preparation and Viewing Pipeline
Norgan, Andrew P. , Shah, Kabeer , Maleszewski, Joseph J. , Norgan, Andrew Paul, Shah, Kabeer Kevin, Juskewitch, Justin Eddie, Maleszewski, Joseph John, Norgan, Andrew P , Juskewitch, Justin E.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | November 30, 2018 | Volume: 142 | Issue: 12 | Pages: 1454-1455

10.5858/arpa.2018-0323-le | PMID 30500278 Get It

Targeting HER2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy
Harris, Faye R. , Zhang, Piyan , Yang, Lin , Hou, Xiaonan , Leventakos, Konstantinos , Weroha, Saravut J., Vasmatzis, George , Kovtun, Irina V.

Mayo Clinic

Molecular Oncology | November 30, 2018 | Volume: 13 | Issue: 2 | Pages: 132-152

10.1002/1878-0261.12414 | PMID 30499260 Get It

Ovarian cancer is the most lethal gynecologic malignancy. About 75% of ovarian cancer patients relapse and/or develop chemo‐resistant disease after initial response to standard‐of‐care treatment with platinum‐based therapies. HER2 amplifications and overexpression in ovarian cancer are reported to vary, and responses to HER2 inhibitors have been poor. Next generation sequencing technologies in conjunction with testing using patient‐derived xenografts (PDX) allow validation of personalized treatments. Using a whole‐genome mate‐pair next generation sequencing (MPseq) protocol, we identified several high grade serous ovarian cancers (HGS‐OC) with DNA alterations in genes encoding members of the ERBB2 pathway. The efficiency of anti‐HER2 therapy was tested in three different PDX lines with the identified alterations and high levels of HER2 protein expression. Treatment responses to pertuzumab or pertuzumab/trastuzumab were compared in each PDX line WITH standard carboplatin and paclitaxel combination treatment. In all three PDX models, HER2‐targeted therapy resulted in significant inhibition of tumor growth compared with untreated controls. However, the responses in each case were inferior to those to chemotherapy, even for chemo‐resistant lines. When chemotherapy and HER2‐targeted therapy were administered together, a significant regression of tumor was observed after 6 weeks of treatment compared with chemotherapy alone. Post‐treatment analysis of these tissues revealed that inhibition of the ERBB2 pathway occurred at the level of phosphorylation and expression of downstream targets. In conclusion, while targeting of presumably activated ERBB2 pathway alone in HGS‐OC results in a modest treatment benefit, a combination therapy including both chemotherapy drugs and HER2 inhibitors provides a far better response. Further studies are needed to address development of recurrence and sensitivity of recurrent disease to HER2‐targeted therapy.
A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants
Jensen, Allan , Wiensch, Ashley , Lee, Alice W. , Ness, Roberta B., Salvatore, Maxwell , Tworoger, Shelley S. , Whittemore, Alice S. , Sieh, Weiva , Goode, Ellen L. , Goodman, Marc T. , Chenevix‐Trench, Georgia , Rossing, Mary Anne, Webb, Penelope M. , Terry, Kathryn L. , Fortner, Renée T. , Menon, Usha , Gayther, Simon A. , Wu, Anna H. , Song, Honglin , Brooks‐Wilson, Angela , Thompson, Pamela J., Chang‐Claude, Jenny , Schildkraut, Joellen M. , Le, Nhu D. , Wentzensen, Nico, Trabert, Britton , Høgdall, Estrid , Huntsman, David G. , Pike, Malcolm C. , Pearce, Celeste Leigh , Salvatore, Maxwell , Anton-Culver, Hoda , Goode, Ellen L , Fortner, Renée T , Wu, Anna H. , Cramer, Daniel W , Modugno, Francesmary , Trabert, B , Pike, Malcolm C , Pearce, Celeste Leigh , Tworoger, Shelley S , Webb, Penelope M , Jensen, Allan , Menon, Usha , Brooks-Wilson, Angela R , Sieh, Weiva , Chenevix-Trench, Georgia , Høgdall, Estrid , Goodman, Marc T , Kim, Sehee , Wang, Miao , Tyrer, Jonathan P. , Liu, Gang , Anton‐Culver, Hoda , Olson, Sara H. , Berchuck, Andrew , Doherty, Jennifer A. , Giles, Graham G. , Ziogas, Argyrios , Bandera, Elisa V. , Cook, Linda S. , Cramer, Daniel W. , Milne, Roger L. , Winham, Stacey J. , Kjær, Susanne K. , Modugno, Francesmary , Harris, Holly R. , Pharoah, Paul D.P. , Mukherjee, Bhramar

Mayo Clinic

International Journal of Cancer | November 30, 2018 | Volume: 144 | Issue: 9 | Pages: 2192-2205

10.1002/ijc.32029 | PMID 30499236 Get It

As a follow‐up to genome‐wide association analysis of common variants associated with ovarian carcinoma (cancer), our study considers seven well‐known ovarian cancer risk factors and their interactions with 28 genome‐wide significant common genetic variants. The interaction analyses were based on data from 9971 ovarian cancer cases and 15,566 controls from 17 case–control studies. Likelihood ratio and Wald tests for multiplicative interaction and for relative excess risk due to additive interaction were used. The top multiplicative interaction was noted between oral contraceptive pill (OCP) use (ever vs. never) and rs13255292 (p value = 3.48 × 10−4). Among women with the TT genotype for this variant, the odds ratio for OCP use was 0.53 (95% CI = 0.46–0.60) compared to 0.71 (95%CI = 0.66–0.77) for women with the CC genotype. When stratified by duration of OCP use, women with 1–5 years of OCP use exhibited differential protective benefit across genotypes. However, no interaction on either the multiplicative or additive scale was found to be statistically significant after multiple testing correction. The results suggest that OCP use may offer increased benefit for women who are carriers of the T allele in rs13255292. On the other hand, for women carrying the C allele in this variant, longer (5+ years) use of OCP may reduce the impact of carrying the risk allele of this SNP. Replication of this finding is needed. The study presents a comprehensive analytic framework for conducting gene–environment analysis in ovarian cancer.
Digital storytelling for hematology education: Interactive thalassemia module for graduate millennial learners
Marshall, Ariela L. , Mann, Susan, Wolanskyj, Alexandra P. , Wolanskyj-Spinner, Alexandra, Marshall, Ariela , Wolanskyj-Spinner, Alexandra P

Mayo Clinic

American Journal of Hematology | November 30, 2018 | Volume: 94 | Issue: 2 | Pages: No page available

10.1002/ajh.25368 | PMID 30499238 Get It

Laboratory Antimicrobial Stewardship During an Outbreak of Linezolid- and Vancomycin-resistant Enterococcus faecium Bacteremia
Schuetz, Audrey N.

Mayo Clinic

Clinical Infectious Diseases | November 30, 2018 | Volume: 69 | Issue: 2 | Pages: 266-267

10.1093/cid/ciy1023 | PMID 30576431 Get It

Optimizing survival of large fibula osteocutaneous flaps for extensive full‐thickness oromandibular defects: A two‐stage approach with temporary orocutaneous fistula
Ciudad, Pedro , Huang, Tony Chieh‐Ting , Manrique, Oscar J. , Agko, Mouchammed , Adabi, Kian , Nicoli, Fabio , Saçak, Bülent , Kiranantawat, Kidakorn , Moran, Steven L. , Mouchammed, Agko , Chen, Hung‐Chi

Mayo Clinic

Microsurgery | November 29, 2018 | Volume: 39 | Issue: 3 | Pages: 234-240

10.1002/micr.30386 | PMID 30496605 Get It

IntroductionComposite and large head and neck defects requiring extensive skin‐mucosa coverage are often reconstructed by combining flaps. Herein, we present a simple and reliable two‐stage fibula osteocutaneous (FOC) flap technique to improve the survival of a large skin paddle for oromandibular reconstructions.MethodsFrom October 2011 to September 2016, 47 patients with through‐and‐through oromandibular defects were reconstructed using FOC flaps with large skin paddles. To ensure optimum survival of skin paddles, temporary orocutaneous fistula were left in place and closed during the second stage operation via de‐epithelialization of the skin paddle and suturing of mucosa. Demographic data, operative details, and postoperative complications were recorded.ResultsThe skin paddle dimensions ranged from 20 to 31.5 cm in length and 12 to 17 cm in width with an average area of 430.4 cm2 (range 300–504). The average time between the two stages and hospital stay were 10 days and 14 days, respectively. Complications at the donor site included wound dehiscence (n = 3, 6.4%), partial skin graft loss (n = 3, 6.4%) and hematoma (n = 2, 4.3%). Recipient site complications included two (4.3%) early postoperative venous congestions that resolved after elevation and three (6.4%) partial skin flap necrosis (less than 5% surface area). All complications resolved with bedside conservative management. There was only one take‐back for evacuation of recipient site hematoma (2.1%) but no flap loss.ConclusionTwo‐staged large skin paddle FOC flaps can simplify reconstruction of extensive oromandibular defects by improving the reliability of the sizable skin paddle and negating the need for a second flap.
Masses in the era of screening tomosynthesis: Is diagnostic ultrasound sufficient?
Choudhery, Sadia, Axmacher, Jessica A, Conners, Amy Lynn , Geske, Jennifer R. , Brandt, Kathy R., Axmacher, Jessica, Geske, Jennifer, Brandt, Kathy, Geske, Jennifer

Mayo Clinic

The British Journal of Radiology | November 29, 2018 | Volume: 92 | Issue: 1096 | Pages: No page available

10.1259/bjr.20180801 | PMID 30495975 Get It

Objectives: The purpose of this study is to compare diagnostic outcomes of digital breast tomosynthesis screen-detected masses worked up with mammography first with those evaluated with diagnostic ultrasound initially. Methods: All masses recalled from screening digital breast tomosynthesis between July 1, 2017 and December 31, 2017 that were sent either to diagnostic mammography or ultrasound were compared. Size, shape, margins, visibility on ultrasound, diagnostic assessment and pathology of all masses along with breast density were evaluated. Results: 102/212 digital breast tomosynthesis screen-detected masses were worked up with diagnostic mammography initially and 110/212 were worked up with ultrasound directly. There was no significant difference in ultrasound visibility of masses sent to diagnostic mammography first with those sent to ultrasound first (p = 0.42). 4 (4%) masses sent to mammogram first and 2 (2%) masses sent to ultrasound first were not visualized. There was a significant difference in size between masses that were visualized under ultrasound versus those that were not (p = 0.01), when masses in both groups were assessed cumulatively. Conclusions: 98% of digital breast tomosynthesis screen-detected masses sent to ultrasound directly were adequately assessed without diagnostic mammography. Advances in knowledge: There is potential for avoiding a diagnostic mammogram for evaluation of majority of digital breast tomosynthesis screen-detected masses.
B cell homeostasis is maintained during long-duration spaceflight
Spielmann, Guillaume , Agha, Nadia H. , Kunz, Hawley , Simpson, Richard J. , Crucian, Brian, Mehta, Satish , Campbell, John P. , Simpson, Richard J , Kunz, Hawley E , Laughlin, Mitzi S.

Mayo Clinic

Journal of Applied Physiology | November 29, 2018 | Volume: 126 | Issue: 2 | Pages: 469-476

10.1152/japplphysiol.00789.2018 | PMID 30496712 Get It

Long-duration spaceflights reportedly induce immune dysregulation, which is considered a risk to astronaut safety and mission success. Recent studies have examined the impact of spaceflight on markers of adaptive and innate immunity, but no study, to date, has comprehensively evaluated humoral immunity and serological markers of B cell function. The aim of this study was to characterize changes in B cell numbers and phenotypes, along with plasma Igs and polyclonal free light chains (FLCs)—near-“real-time” biomarkers of Ig synthesis—in response to an ~6-mo mission to the International Space Station (ISS). Whole-blood samples were collected before flight, during flight (“Early flight,” “Mid-flight,” and “Late flight”), immediately upon return, and during a recovery period (R + 18, R + 30/R + 33, and R + 60/R + 66) from 23 ISS crew members. B Cell counts and phenotypes were measured throughout the duration of the mission, along with total plasma Ig and FLC levels. There was no effect of spaceflight on the number and proportion of the different B cell subsets. There was no difference in kappa FLC between preflight samples and either in-flight or recovery samples ( P > 0.05), and only a marginal reduction was observed in lambda FLC levels upon return to Earth ( P < 0.05). Furthermore, IgG and IgM remained unchanged during and after spaceflight compared with preflight values ( P > 0.05). Of note, plasma IgA concentrations were elevated in-flight compared with baseline and recovery values ( P < 0.05). These results indicate that B cell homeostasis is maintained during long-duration spaceflight, advocating for potential in-flight vaccination as viable countermeasures against viral reactivation during exploration-class missions.